Prevalence and antimicrobial susceptibility of extended-spectrum beta lactamases-producing Escherichia coli and Klebsiella pneumoniae isolated in selected hospitals of Anyigba, Nigeria

Abstract

Background: Escherichia coli and Klebsiella pneumoniae are commonly implicated in urinary tract infections accounting for majority of the antimicrobial resistance encountered in hospitals.
 Objectives: To determine the prevalence and antimicrobial susceptibility of extended-spectrum beta-lactamases (ESBLs) producing E. coli and K. pneumoniae among patients in Anyigba, Nigeria.
 Methods: This hospital-based cross-sectional study was conducted using urine samples from 200 patients of Grimmard Catholic hospital and Maria Goretti hospital. Urine samples were processed to identify ESBL-producing E. coli and K. pneu- moniae using standard microbiological techniques. Isolates were then tested against antimicrobial agents.
 Results: A total of 156 bacterial isolates were recovered consisting 128 of E. coli and 28 of K. pneumoniae. Extended spec- trum beta-lactamases production was observed in 69% of E. coli and 31% of K. pneumoniae. These pathogens were resistant to 3 or more antibiotics. Of the antimicrobials tested, cefotaxime demonstrated the highest rates of resistance (100%) for both ESBL-producing E. coli and K. pneumoniae. Fifty-four isolates of ESBL-producing E. coli showed a high level of resist- ance to amoxicillin clavulanic acid (83.3%), ciprofloxacin (83.3%), and ceftazidime (79.6%). ESBL-positive K. pneumoniae iso- lates were highly resistant to ciprofloxacin (75%), and amoxicillin clavulanic acid (83.3%). Cefoxitin (62.5%) and gentamicin (66.7%) showed substantially higher rates of resistance against these isolates while all 24 strains were resistant to imipenem.
 Conclusion: This study indicated the prevalence of ESBL-positive Gram-negative pathogens in these study sites and also demonstrated their resistance to a few antibiotics. This highlights the need for new antimicrobials that are potent and im- proved policy on use of antibiotics.
 Keywords: Antibiotic resistance; ESBLs; Escherichia coli; Klebsiella pneumoniae; Anyigba.

Novel Graphene Oxide/Quercetin and Graphene Oxide/Juglone Nanostructured Platforms as Effective Drug Delivery Systems with Biomedical Applications

“…Therefore, novel solutions and compounds need to be utilized in order to keep up with the evolution of bacterial resistance mechanisms. A prevalence of S. aureus, E. coli, and C. albicans infections associated with the biomedical field has been reported by several authors [ 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 ].…”

Study of The Anti-bacterial Efficacy of Probiotics Culture Extracts on Extended Spectrum Beta Lactamase-Producing Multi-Drug Resistant Isolates, Bearing BLA-TEM-1 Gene, in Patients with Wound Infections in Hospitals

“…Extended Spectrum βeta Lactamase are enzymes have the ability to develop microorganism resistance to penicillins, all generations of cephalosporins, and monobactams as they can hydrolyze those antimicrobial drugs. In addition, they do not affect carbapenems [1] .…”

Enterobacterias productoras de betalactamasas de espectro extendido, aisladas en hemocultivos de pacientes atendidos en diferentes áreas hospitalarias

“…En pacientes colonizados, por lo general, se inician tratamientos empíricos no adecuados, lo cual consecuentemente podría conducir a sepsis. Dentro de los microorganismos en los que se ha reportado resistencia a los antimicrobianos se encuentran las enterobacterias, bacilos gramnegativos capaces de producir BLEE (7).…”